PharmaCom BioVet, Inc. Begins To Review The Process To Potentially Receive Minor Use/Minor Species Drug Approval From FDA
Main Category: VeterinaryAlso Included In: Regulatory Affairs / Drug Approvals
Article Date: 14 Jun 2009 - 2:00 PDT
| Patient / Public: | ![]() |
4.17 (6 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce that the Company has begun the process to potentially apply and endeavor to receive a Minor Use/Minor Species (MUMS) drug approval from the Federal Drug Administration (FDA). Meeting the MUMS requirement is part of the New Drug Approval Process if the Company decides to potentially run clinical trials on a histone deacetylase inhibitor for canines with hemangiosarcoma, which the Corporation is considering the development of. The histone deacetylase inhibitor would be directed for dogs suffering from an acute type of cancer, canine hemangiosarcoma. The Minor Use and Minor Species Animal Health Act became law in 2004.
Minor uses are based on there being a small number of animals eligible for treatment with the product in question for the specific intended use. Small numbers have been determined for each of the 7 major species (cows, horses, pigs, chickens, turkeys, dogs, and cats). These have been published in a proposed rule (http://www.fda.gov/OHRMS/DOCKETS/98fr/E8-5385.pdf). To determine if a use is minor, the standard is that the intended use is for a "small number of animals." There is a different "small number" for each of the 7 major species and it reflects the number of animals affected by the disease over a one-year period.
"We are continuing to review the FDA filing requirements in order to determine if we may meet the requirements stated by the MUMS Act. By doing so, we potentially progress closer to being able to begin the testing of a novel cancer treatment for canines with Hemangiosarcoma," stated Gary S. Berthold, President of PharmaCom BioVet, Inc.
Source
PharmaCom BioVet, Inc.
Visit our veterinary section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/153759.php>
APA
http://www.medicalnewstoday.com/releases/153759.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




